Immix Biopharma reports 2026 shareholder vote results
Immix Biopharma, Inc. reported the final voting results from its 2026 Annual Meeting of stockholders held on May 22, 2026.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Form Type
8-K
Rhea-AI Filing Summary
Immix Biopharma, Inc. reported the final voting results from its 2026 Annual Meeting of stockholders held on May 22, 2026. Stockholders elected all listed director nominees, including Ilya Rachman, Gabriel Morris and others, with each receiving over 34 million votes in favor and relatively few votes withheld.
Each director election also recorded 6,445,683 or 6,445,684 broker non-votes. A second proposal was approved with 42,276,496 votes for, 11,526 against and 18,442 abstentions, indicating strong support from voting shareholders for the matters presented.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Votes for Jason Hsu: 35,844,812 votes
Votes for Ilya Rachman: 35,738,887 votes
Typical broker non-votes for directors: 6,445,684 votes
+3 more
6 metrics
Votes for Jason Hsu
35,844,812 votes
Director election at 2026 Annual Meeting
Votes for Ilya Rachman
35,738,887 votes
Director election at 2026 Annual Meeting
Typical broker non-votes for directors
6,445,684 votes
Broker non-votes on director elections
Votes for second proposal
42,276,496 votes
Proposal 2 at 2026 Annual Meeting
Votes against second proposal
11,526 votes
Proposal 2 at 2026 Annual Meeting
Abstentions on second proposal
18,442 votes
Proposal 2 at 2026 Annual Meeting
Key Terms
broker non-votes, Emerging growth company, Definitive Proxy Statement, Schedule 14A, +1 more
5 terms
broker non-votes financial
"Each director line shows For, Withheld and Broker Non-Votes figures."
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
Emerging growth company regulatory
"Emerging growth company appears near the registrant status check section."
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
Definitive Proxy Statement regulatory
"These matters are described in more detail in the Definitive Proxy Statement on Schedule 14A."
A Definitive Proxy Statement is a detailed document that a company sends to its shareholders before a big meeting, like voting on important decisions. It explains what's being voted on and gives important information so shareholders can make informed choices. It matters because it helps shareholders understand and participate in key company decisions.
Schedule 14A regulatory
"Described in more detail in the Definitive Proxy Statement on Schedule 14A filed by the Company."
Schedule 14A is a document that companies file with regulators to share important information with shareholders before a big vote, like approving a merger or election of directors. It matters because it helps investors understand what’s happening so they can make informed decisions about the company’s future.
Annual Meeting financial
"On May 22, 2026, at the 2026 Annual Meeting of stockholders of Immix Biopharma, Inc."
A company's annual meeting is a yearly gathering where owners (shareholders) and the board review performance, ask questions, and vote on key matters like electing directors, approving auditor choices, and sometimes setting pay or dividend policies. For investors it matters because decisions made and votes cast can change who runs the company, influence strategy and payouts, and affect the value or direction of their investment—similar to a homeowners’ meeting where rules and leaders that shape your property’s value are decided.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What did Immix Biopharma (IMMX) announce in this 8-K filing?
Immix Biopharma reported the final results of stockholder voting from its 2026 Annual Meeting. The filing shows all director nominees were elected and a second proposal passed with strong support, detailing votes for, against, abstentions, and broker non-votes.
Were Immix Biopharma (IMMX) director nominees elected at the 2026 Annual Meeting?
Yes, all listed director nominees were elected at the 2026 Annual Meeting. Each nominee received more than 34 million votes for, with relatively small withheld totals and over 6.44 million broker non-votes reported for the director elections in the filing.
How many votes supported Immix Biopharma’s second proposal at the 2026 meeting?
The second proposal received 42,276,496 votes for, 11,526 votes against, and 18,442 abstentions. No broker non-votes were recorded on this proposal, indicating strong approval among the shares that were entitled to and did vote on the item.
When was Immix Biopharma’s 2026 Annual Meeting of stockholders held?
Immix Biopharma’s 2026 Annual Meeting of stockholders was held on May 22, 2026. The disclosed 8-K summarizes results for director elections and a second proposal, referencing additional details contained in the company’s Definitive Proxy Statement filed earlier that year.
What are broker non-votes in Immix Biopharma’s 2026 voting results?
Broker non-votes occur when brokers hold shares but do not have instructions to vote on specific proposals. For Immix Biopharma’s director elections, about 6,445,683 or 6,445,684 broker non-votes were recorded per nominee, meaning those shares were not counted as for or against.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Accepted by SEC EDGAR
Learn about SEC filing dates